Moreover, we establish that PIM inhibition results in suppressive effects on primary leukemic progenitors from CML patients, further suggesting a potential role for PIM targeting as a novel therapeutic approach for Ph+ leukemias. This evidence concerns the gene PIM1 and chronic myelogenous leukemia, BCR-ABL1 positive.